Although pneumococcal polysaccharide vaccine is a standard ... 22 randomized trials with 100,000 subjects. The current 23-valent vaccine was used in eight trials, and previous lower-valent ...

Pregnant patients in their third trimester and postpartum women showed higher risk for IPD compared with nonpregnant patients.

Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines, taking a 21-valent ... older, polysaccharide-based jab Pneumovax 23.

The rivalry between Pfizer and MSD in pneumococcal vaccines ... an older shot called Pneumovax 23, which covers 23 serotypes, but is based on an older polysaccharide technology that does not ...

For prevention of IPD, the National Advisory Committee on Immunization (NACI) has recommended the 23-valent polysaccharide pneumococcal vaccine, PNEU-P-23, for adults 65 years of age and older and ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive ...

Advisory Committee on Immunization Practices (ACIP) has lowered the recommended age for pneumococcal vaccination from 65 to ...

Based on country-level data from the following four EU countries, the serotypes covered by CAPVAXIVE are responsible for more cases of IPD in adults compared to PCV20 (pneumococcal 20-valent ...

Merck MRK announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its 21-valent pneumococcal conjugate vaccine ...

Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults ...